TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 793549
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment (aortocoronary bypass)
Study: 25982678
Drug: Thiamine supplementation
Normalized name: thiamine
DrugBank: Thiamine (DB00152)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thiamine supplementation (3 × 100 mg/day for six weeks)
Study: 15624735
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy (PDT) with 5-aminolevulinic acid (ALA) and blue light (405-420 nm) for 15 minutes
Study: 15624735
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy (PDT) with 5-aminolevulinic acid (ALA) and intense pulsed light (IPL, 500-1,200 nm)
Study: 10843478
Drug: Colposcopy after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colposcopy after therapy
Study: 9171795
Drug: Coaxial catheter
Normalized name: CATHETER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coaxial catheter method for sequential spiral CT during arterial portography (CTAP) and hepatic arteriography (CTA)
Study: 9171795
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of CTAP and CTA
Study: 3281786
Drug: Oral verapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral verapamil alone at a dose of 80 mg three times daily
Study: 3281786
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 40 mg of verapamil three times daily with 0.25 mg of digoxin daily
Study: 28555092
Drug: Tetrodotoxin (TTX)
Normalized name: Tetrodotoxin
DrugBank: Tetrodotoxin (DB05232)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetrodotoxin (TTX) 30 μg subcutaneously twice daily for four consecutive days
Study: 28555092
Drug: Placebo subcutaneously
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo subcutaneously twice daily for four consecutive days
Study: 21646935
Drug: Vestipitant and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vestipitant and Paroxetine combination
Study: 17070157
Drug: Probucol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probucol (1 g/d)
Study: 14628586
Drug: Acupuncture (AC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture (AC) combined with drug therapy
Study: 14628586
Drug: Combined drug
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined drug therapy
Study: 10902992
Drug: E =
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: E = 1171 kJ + 12 mg iron
Study: 10902986
Drug: M =
Normalized name: Methadone
DrugBank: Methadone (DB00333)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: M = 209 kJ + 12 mg iron
Study: 24028708
Drug: Low calcium
Normalized name: Dianeal Low Calcium 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low calcium dialysate (1.25 mmol/L)
Study: 24028708
Drug: Standard calcium
Normalized name: Stangard
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard calcium dialysate (1.75 mmol/L)
Study: 22376791
Drug: Rest therapy
Normalized name: Rest Simply
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rest therapy for 10 weeks with a recommendation to rest for two hours daily and the option of using a flexible lumbar belt
Study: 22376791
Drug: Exercise therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise therapy once a week for 10 weeks
Study: 20888994
Drug: Chemotherapy (fludarabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (fludarabine and cyclophosphamide)
Study: 18391846
Drug: Indomethacin treatment
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indomethacin treatment for 3 months
Study: 11964956
Drug: 0.4 g/dL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 g/dL oligosaccharides
Study: 11964956
Drug: 0.8 g/dL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8 g/dL oligosaccharides
Study: 10214007
Drug: Continuous epidural
Normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous epidural infusion for 2 postoperative days (group B 2)
Study: 10214007
Drug: Continuous epidural
Normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous epidural infusion for 4 postoperative days (group B 4)
Study: 29510745
Drug: Autologous dendritic
Normalized name: COVID19 s-vax loaded autologous dendritic cell vaccine
DrugBank: COVID19 s-vax loaded autologous dendritic cell vaccine (DB15814)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous dendritic cell vaccines (DCV) with 500 micrograms of GM-CSF, injected weekly for 3 weeks, then at weeks 8, 12, 16, 20, and 24.
Study: 29510745
Drug: Autologous tumor
Normalized name: DNP-Modified autologous tumor vaccine
DrugBank: DNP-Modified autologous tumor vaccine (DB17436)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous tumor cell vaccines (TCV) with 500 micrograms of GM-CSF, injected weekly for 3 weeks, then at weeks 8, 12, 16, 20, and 24.
Study: 26828571
Drug: Cognitive training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive training plus work therapy (n = 15)
Study: 26828571
Drug: Work therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Work therapy alone (n = 16)
Study: 7851108
Drug: Experimental treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental treatment E
Study: 7851108
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment S
Study: 3132551
Drug: Flumazenil (0.10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumazenil (0.10 mg/kg)
Study: 3132551
Drug: Flumazenil (0.20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumazenil (0.20 mg/kg)
Study: 25640664
Drug: Prednisolone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (50 mg for 10 days)
Study: 19968391
Drug: Best practice
Normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best practice treatment conditions
Study: 12217455
Drug: Low-dose alcohol
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose alcohol
Study: 12217455
Drug: High-dose alcohol
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose alcohol
Study: 7994447
Drug: Hydrochlorothiazide 3
Normalized name: hydrochlorothiazide 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide 3 mg
Study: 7994447
Drug: Hydrochlorothiazide 6
Normalized name: hydrochlorothiazide 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide 6 mg
Study: 14686231
Drug: Preemptive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preemptive therapy
Study: 28683833
Drug: Skin-to-skin contact
Approvals — FDA: no, EMA: no, PMDA: no
Description: Skin-to-skin contact (SSC) for at least one continuous hour daily for 5 weeks
Study: 20039456
Drug: Acupuncture (once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture (once daily, starting on postoperative day 1, for up to six consecutive days)
Study: 11821089
Drug: Ellios pessaries
Normalized name: Ellis Tonic
DrugBank: Zinc sulfate, unspecified form (DB14548)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ellios pessaries (2 times 200‐mg pessary/day)
Study: 11821089
Drug: Utrogestan capsules
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Utrogestan capsules (2 x 100‐mg capsules, two times a day)
Study: 2475688
Drug: Slow-release verapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow-release verapamil (SR) 240 mg q.i.d.
Study: 2475688
Drug: Immediate-release verapamil
Normalized name: verapamil Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release verapamil (IR) 80 mg t.i.d.
Study: 2475688
Drug: Immediate-release verapamil
Normalized name: verapamil Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release verapamil (IR) 480 mg/day
Study: 23731168
Drug: Naftopidil (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naftopidil (75 mg/day)
Study: 23731168
Drug: Silodosin (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silodosin (8 mg/day)
Study: 31741279
Drug: Tablet animation
Normalized name: monofluorophosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet animation format of the CHU-9D questionnaire
Study: 31741279
Drug: Tablet image
Normalized name: triclosan
DrugBank: Triclosan (DB08604)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablet image format of the CHU-9D questionnaire
Study: 27241836
Drug: Aspirin supplementation
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin supplementation
Study: 19193422
Drug: Finasteride 5
Normalized name: finasteride 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finasteride 5 mg plus alfuzocin 10 mg or tamsulosin 0.2 mg daily (group 1)
Study: 19193422
Drug: Dutasteride 0.5
Normalized name: dutasteride 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dutasteride 0.5 mg plus alfuzocin 10 mg or tamsulosin 0.2 mg daily (group 2)
Study: 15296472
Drug: Surgical and/or
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical and/or medical therapy for acromegaly
Study: 15296472
Drug: No therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: No therapy (noncontrolled patients)
Study: 9059403
Drug: Iodixanol (13.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iodixanol (13.5 g I)
Study: 9059403
Drug: Iopromide (15.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iopromide (15.0 g I)
Study: 3767008
Drug: Oral ranitidine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ranitidine, 150 mg, with 150 ml water
Study: 3767008
Drug: Oral ranitidine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ranitidine, 150 mg, with no further fluid
Study: 3829296
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with 150 ml water
Study: 3767008
Drug: 150 ml
Normalized name: REBYOTA 150 ML Enema
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 ml water with placebo
Study: 30267481
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with Surgicel and histamine‐2 receptor antagonist (H2 RA)
Study: 30267481
Drug: Monotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy with a proton pump inhibitor (PPI)
Study: 30267481
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with Surgicel and H2 RA
Study: 27727157
Drug: Single-dose maraviroc
Normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose maraviroc 300 mg
Study: 24850603
Drug: α‐lipoic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: α‐lipoic acid (600 mg/day) in addition to basic therapy
Study: 22842339
Drug: BDP/FF 100/6
Approvals — FDA: no, EMA: no, PMDA: no
Description: BDP/FF 100/6 μg in pressurised metered-dose inhaler (pMDI) extrafine formulation
Study: 22842339
Drug: Salbutamol 200
Normalized name: Salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salbutamol 200 μg pMDI
Study: 12718708
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of DB and PLB (CB)
Study: 10325912
Drug: Inhaled corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroids (budesonide 600 micrograms daily)
Study: 9061129
Drug: Gericomplex (ginseng,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gericomplex (ginseng, vitamins, minerals and trace elements) - 2 capsules daily for 8 weeks
Study: 9061129
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules - identical in appearance to Gericomplex
Study: 31343585
Drug: Weekly unsupervised
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly unsupervised WCD-guided 6MWTs at home
Study: 28497756
Drug: S-1 (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 (80 mg/m2, 80-120 mg per day, twice daily for 28 days)
Study: 24439462
Drug: Intravitreal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal therapy using ranibizumab (n = 11)
Study: 24439462
Drug: Intravitreal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal therapy using bevacizumab (n = 20)
Study: 24439462
Drug: Intravitreal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal therapy using triamcinolone (n = 19)
Study: 24439462
Drug: Intravitreal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal therapy (all types combined)
Study: 19178624
Drug: Control group:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group: metal matrix containing two implants
Study: 11442739
Drug: Subantimicrobial dose
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subantimicrobial dose doxycycline (SDD) 20 mg bid
Study: 9439561
Drug: Sulfonylurea therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfonylurea therapy (gliclazide, ≤ 160 mg.d‐1)
Study: 9439561
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (double-blind placebo or no tablets)
Study: 2438647
Drug: PCOP combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCOP combination for 6 months followed by chlorambucil or CVP for 12 months
Study: 2438647
Drug: Combined use
Normalized name: CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined use of interferon and chemotherapy (proposed for future trials)
Study: 26936907
Drug: Spironolactone 25
Normalized name: spironolactone 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone 25 mg once daily
Study: 28690028
Drug: Meropenem (MEPM)
Normalized name: Meropenem
DrugBank: Meropenem (DB00760)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Meropenem (MEPM) with or without intravenous immunoglobulin (IVIG)
Study: 22424400
Drug: Cognitive-behaviour group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behaviour group therapy (15-week manualized group therapy)
Study: 22424400
Drug: Waiting list
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waiting list (4 months without treatment)
Study: 18582254
Drug: mannitol 0.5
Normalized name: MANNITOL 0.54%/SORBITOL 2.7% IRRG SOLN
Approvals — FDA: no, EMA: no, PMDA: no
Description: mannitol 0.5 g.kg(‐1)
Study: 18477268
Drug: Hartmann's solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hartmann's solution (control)
Study: 11821704
Drug: High-sodium tap
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-sodium tap water (HSTW) with sodium concentration of 196 mg/l (8.5 mmol/l)
Study: 11821704
Drug: Low-sodium mineral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-sodium mineral water (LSMW) with sodium concentration of 32 mg/l (1.4 mmol/l)
Study: 7742841
Drug: Ultrasound treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound treatment on precooled tissue (preceded by 5 minutes of ice)
Study: 7742841
Drug: Ultrasound with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound with no preceding treatment
Study: 2258042
Drug: Chlorpheniramine (antihistamine)
Normalized name: Ahist Antihistamine
DrugBank: Chlorpheniramine (DB01114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpheniramine (antihistamine)
Study: 2258042
Drug: Placebo (cherry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (cherry syrup)
Study: 25650051
Drug: 340 mg
Normalized name: febantel 340 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 340 mg ADS‐5102
Study: 25650051
Drug: 260 mg
Normalized name: aspirin 260 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 260 mg ADS‐5102
Study: 25650051
Drug: 420 mg
Normalized name: choline 420 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 420 mg ADS‐5102
Study: 9108813
Drug: Paroxetine 20-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine 20-40 mg/day
Study: 12096198
Drug: Inhaled methacholine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled methacholine (MCh) after allergen challenge
Study: 12096198
Drug: Inhaled cysteinyl
Normalized name: bis(cysteinyl maleimide) PEG 20000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled cysteinyl leukotriene D(4) (LTD(4)) after allergen challenge
Study: 12096198
Drug: Inhaled methacholine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled methacholine (MCh) after control
Study: 12096198
Drug: Inhaled cysteinyl
Normalized name: bis(cysteinyl maleimide) PEG 20000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled cysteinyl leukotriene D(4) (LTD(4)) after control
Study: 12096198
Drug: Inhaled cysteinyl
Normalized name: bis(cysteinyl maleimide) PEG 20000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled cysteinyl leukotriene D(4) (LTD(4)) challenge reproducibility
Study: 10492062
Drug: Dipyrone 500
Normalized name: dipyrone 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyrone 500 mg t.i.d.
Study: 8609254
Drug: Topical calcipotriene
Normalized name: calcipotriene Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical calcipotriene ointment (50 microgram/gm, maximum usage, 120 gm per week) for 8 weeks
Study: 27600789
Drug: Mechanical debridement
Normalized name: PIPERONYL BUTOXIDE TECHNICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mechanical debridement with adjunct antimicrobial photodynamic therapy (aPDT)
Study: 25877666
Drug: Terconazole vaginal
Normalized name: terconazole Vaginal Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terconazole vaginal suppository (80 mg for 6 days)
Study: 25877666
Drug: Oral fluconazole
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral fluconazole (150 mg, two doses)
Study: 23704676
Drug: Metformin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin plus rosiglitazone (M + R)
Study: 23704676
Drug: Metformin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin plus lifestyle program (M + L)
Study: 25885385
Drug: Ramosetron 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramosetron 0.3 mg iv
Study: 25885385
Drug: Palonosetron 0.075
Normalized name: palonosetron 0.075 MG in 1.5 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palonosetron 0.075 mg iv
Study: 25885385
Drug: Ondansetron 8
Normalized name: ondansetron 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 8 mg iv
Study: 17526178
Drug: Compound E‐Bei
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound E‐Bei ointment (CEBO)
Study: 10527993
Drug: Intramuscular progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intramuscular progesterone (i.m. progesterone-in-oil preparation)
Study: 8750402
Drug: Aspirin 3900
Normalized name: aspirin 3900 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 3900 mg/d
Study: 8750402
Drug: Bromfenac sodium
Normalized name: Bromfenac Sodium
DrugBank: Bromfenac (DB00963)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bromfenac sodium 300 mg/d
Study: 1777605
Drug: Late intensification
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late intensification therapy (LIT) with high-dose methotrexate (HD-MTX) administered at 2,000 mg/m2 per dose per week, given by 24 h infusion, three doses every 12 weeks.
Study: 26832746
Drug: Lactobacillus reuteri
Normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus reuteri DSM 17938 and Bifidobacterium longum subspecies infantis 35624 (Daily dosing)
Study: 26832746
Drug: Lactobacillus reuteri
Normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus reuteri DSM 17938 and Bifidobacterium longum subspecies infantis 35624 (Weekly dosing)
Study: 26832746
Drug: Lactobacillus reuteri
Normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus reuteri DSM 17938 and Bifidobacterium longum subspecies infantis 35624 (Biweekly dosing)
Study: 24903522
Drug: Rocuronium (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium (0.2 mg/kg)
Study: 9818934
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (plasma exchange and intravenous immunoglobulin)
Study: 7648483
Drug: 100 IU
Normalized name: Vitamin E 100 IU Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 IU salmon calcitonin (5 suppositories per week)
Study: 7648483
Drug: 200 IU
Normalized name: Vitamin E 200 IU Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 IU salmon calcitonin (3 suppositories per week)
Study: 7648483
Drug: Placebo (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (5 suppositories per week)
Study: 7648483
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups received 500 mg/day of calcium supplementation
Study: 1273220
Drug: Butobarbitone 100
Normalized name: butobarbitone 100 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butobarbitone 100 mg
Study: 1273220
Drug: Butobarbitone 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butobarbitone 200 mg
Study: 1273220
Drug: Lactose dummy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactose dummy treatment
Study: 27451467
Drug: Electronic alert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electronic alert system for OAC prescription
Study: 24482066
Drug: Levofloxacin, 500
Normalized name: LevoFLOXacin, 500 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin, 500 mg daily for 30 days
Study: 22508814
Drug: Accelerated radiotherapy
Normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated radiotherapy plus carbogen inhalation and nicotinamide (ARCON)